Variable | Entire cohort, 0–36 months of follow-up | Entire cohort, >36 months of follow-up | ||||
HR (main effect) | HR (main effect) | |||||
95% CI | P value | 95% CI | P value | |||
RA | 0.63 | 0.60 to 0.66 | <0.001 | 1.13* | 1.05 to 1.22 | 0.002 |
AS | 0.62 | 0.50 to 0.77 | <0.001 | 1.01** | 0.76 to 1.33 | 0.958 |
PsA | 0.68 | 0.59 to 0.78 | <0.001 | 1.06* | 0.88 to 1.28 | 0.537 |
SLE | 1.52 | 1.35 to 1.70 | <0.001 | 1.98** | 1.67 to 2.33 | <0.001 |
SSc | 2.27 | 1.89 to 2.74 | <0.001 | 4.24* | 3.19 to 5.63 | <0.001 |
P value for interaction *<0.001; **<0.05.
AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.